what is noom glp 1 companion Med Microdosing GLP-1 for Weight Loss:

This risk is documented in the orlistat Summary of Product Characteristics and has been highlighted by the MHRA, making orlistat generally unsuitable for people with a history of kidney stones or significant CKD

Gallagher: Thank you

Cagrilintide (AM833) Cagrilintide is a long-acting amylin analog designed for once-weekly (OW) SC administration (based on the structure of natural amylin), developed by Novo Nordisk [112]

Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms

GLP-1 RAs, synthetic analogues of endogenous GLP-1, stimulate insulin secretion while inhibiting glucagon release, with additional benefits in gastric emptying and appetite suppression [8, 9]

As a result, you experience prolonged fullness after meals, reducing the frequency and size of your meals